Literature DB >> 22674652

18F-FDG PET/CT for detecting distant metastases in patients with recurrent head and neck squamous cell carcinoma.

Jong Sook Yi1, Jae Seung Kim, Jeong Hyun Lee, Seung-Ho Choi, Soon Yuhl Nam, Sang Yoon Kim, Jong-Lyel Roh.   

Abstract

BACKGROUND: Distant metastases (DMs) increase in patients with recurrent head and neck squamous cell carcinoma (HNSCC). We evaluated the ability of fluorine 18-fluorodeoxyglucose ((18) F-FDG) positron emission tomography/computed tomography (PET/CT) to detect DMs in these patients.
METHOD: We evaluated 82 consecutive patients with histologically confirmed recurrent HNSCC. Patients with previous DMs were excluded. All patients received whole-body (18) F-FDG PET/CT scanning for restaging of recurrent HNSCC and follow-up after salvage surgery. Any suspected DMs were confirmed by histology and further imaging workups. The diagnostic ability of (18) F-FDG PET/CT to detect DMs was assessed.
RESULTS: Of the 82 patients, 14 (17%) had DMs. The lung (93%) and bone (43%) were the most frequent metastatic sites. (18) F-FDG PET/CT correctly diagnosed the presence of DMs in 12 of 14 patients and their absence in 57 of 68 patients. The sensitivity, specificity, accuracy, and positive (PPV) and negative predictive values (NPV) of (18) F-FDG PET/CT for detecting DMs were 86% (95% confidence interval, 57-98%), 84% (72-91%), 84% (74-91%), 52% (30-73%), and 97% (88-99%), respectively.
CONCLUSIONS: (18) F-FDG PET/CT may be useful in the detection of DMs prior to and after salvage surgery in the high-risk patients with recurrent HNSCC.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22674652     DOI: 10.1002/jso.23185

Source DB:  PubMed          Journal:  J Surg Oncol        ISSN: 0022-4790            Impact factor:   3.454


  13 in total

Review 1.  Present and future role of FDG-PET/CT imaging in the management of head and neck carcinoma.

Authors:  Kazuhiro Kitajima; Yuko Suenaga; Kazuro Sugimura
Journal:  Jpn J Radiol       Date:  2015-10-27       Impact factor: 2.374

2.  FDG-PET/contrast-enhanced CT as a post-treatment tool in head and neck squamous cell carcinoma: comparison with FDG-PET/non-contrast-enhanced CT and contrast-enhanced CT.

Authors:  Yuko Suenaga; Kazuhiro Kitajima; Takeaki Ishihara; Ryohei Sasaki; Naoki Otsuki; Ken-Ichi Nibu; Tsutomu Minamikawa; Naomi Kiyota; Kazuro Sugimura
Journal:  Eur Radiol       Date:  2015-07-19       Impact factor: 5.315

Review 3.  The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature.

Authors:  Giovanni Cammaroto; Natale Quartuccio; Alessandro Sindoni; Francesca Di Mauro; Federico Caobelli
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-05-14       Impact factor: 2.503

4.  Down regulation of RhoC by microRNA-138 results in de-activation of FAK, Src and Erk1/2 signaling pathway in head and neck squamous cell carcinoma.

Authors:  Mozaffarul Islam; Jharna Datta; James C Lang; Theodoros N Teknos
Journal:  Oral Oncol       Date:  2014-02-22       Impact factor: 5.337

5.  PET/CT prior to salvage surgery in recurrent head and neck squamous cell carcinoma.

Authors:  A Nøhr; S B Gram; B Charabi; J F Tvedskov; I Wessel; J Friborg; K Håkansson; C von Buchwald; B M Fischer; Jacob H Rasmussen
Journal:  Eur Arch Otorhinolaryngol       Date:  2019-07-11       Impact factor: 2.503

6.  Suberoylanilide hydroxamic acid inhibits growth of head and neck cancer cell lines by reactivation of tumor suppressor microRNAs.

Authors:  Jharna Datta; Mozaffarul Islam; Samidha Dutta; Sounak Roy; Quintin Pan; Theodoros N Teknos
Journal:  Oral Oncol       Date:  2016-03-19       Impact factor: 5.337

7.  Value of positron emission tomography/computed tomography in diagnosis and staging of primary ocular and orbital tumors.

Authors:  Ka-Hoi Hui; Margaret L Pfeiffer; Bita Esmaeli
Journal:  Saudi J Ophthalmol       Date:  2012-10

8.  FDG volumetric parameters and survival outcomes after definitive chemoradiotherapy in patients with recurrent head and neck squamous cell carcinoma.

Authors:  Vasavi Paidpally; Alin Chirindel; Christine H Chung; Jeremy Richmon; Wayne Koch; Harry Quon; Rathan M Subramaniam
Journal:  AJR Am J Roentgenol       Date:  2014-08       Impact factor: 3.959

9.  Atorvastatin inhibits RhoC function and limits head and neck cancer metastasis.

Authors:  Mozaffarul Islam; Smita Sharma; Bhavna Kumar; Theodoros N Teknos
Journal:  Oral Oncol       Date:  2013-05-04       Impact factor: 5.337

10.  Predictive factors for long-term survival in head and neck squamous cell carcinoma patients with distant metastasis after initial definitive treatment.

Authors:  Ho-Seob Kang; Jong-Lyel Roh; Min-Ju Kim; Kyung-Ja Cho; Sang-wook Lee; Sung-Bae Kim; Seung-Ho Choi; Soon Yuhl Nam; Sang Yoon Kim
Journal:  J Cancer Res Clin Oncol       Date:  2015-09-04       Impact factor: 4.553

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.